Get in touch with BioViros
+64 21 402 487

Investor Summary

All in one place



Receive our comprehensive summary and access to additional documents

Get | Wholesale Investor Pack

Investor Summary as .pdf

Investment Round 2023

revenue forecast 2


Fast Delivery of Investor Updates and Support

Investment Process
  1. Get wholesale investor pack now
  2. Meet the founder
  3. Sign CDA and access Data Room
  4. Complete due diligence
  5. Close the deal
Estimated time to close: 3 months


NZ$ 2.5M Bridge Round
NZ$ 0.5M Committed Funding

August 2023


Lentivirus Manufacturing in APAC

Updated August 2023

Cell and Gene Therapy Market

NZ$ 30.8B in 2022
NZ$ 115.1B by 2030
22.4% CAGR

Updated August 2023

Use of Funds

Secure a GMP facility for clinical grade production, improve the yield, onboard customers for 2024 production.

.Get Wholesale Investor Pack -->|

David Downs (no right)

Our Mission

Living without cancer

With our partners we are aiming to make significant strides towards a world with effective and affordable cancer treatment.

With few month's to live David was lucky enough to receive CAR-T therapy treatment in time. Watch his journey and how cell therapy saved his life. 

Watch David on TEDx

Instant result: No more cancer has been detected after chemo left David few month's to live.

"I am very lucky"

The journey became an experience that David loves to share. "The cost of treatment has to come down".

Our Goal

With our network of partners we aim to develop immunotherapy that is accessible to anyone. 



.Get Wholesale Investor Pack -->|

Back view of businesswoman working with modern virtual technologies

To Market Strategy

We use some of the most advanced AI and customer engagement products available to make each customer interaction efficient and meet our customers' requirements with greater accuracy.

Customer Focus

Every website visitor has an intent. Through segmentation we understand that intent and are able to deliver what is required for each customer to do business with us. 

100% Market Reach

We use AI and traditional methods to identify ideal customers and engage them in personal and customized conversations.

A/B Testing & Smart Segmentation

With every step through our online visitor journey we understand more about our customers. Each click helps us to record preferences and use them to deliver relevant and accurate information in record time. 


  • HubSpot CRM
  • HubSpot CMS
  • Chat GPT-4
  • ChatSpot AI
  • Bing Image AI
  • Vidyo AI
  • Google Analytics


  • AI Page Optimizations
  • AI Content Optimization
  • Live Chat
  • Chat Bots
  • Smart CTAs
  • Cookie Tracking
  • Segmentation
  • Custom Content Delivery
  • Direct Mail

.Get Wholesale Investor Pack -->|

Scientists team at modern hospital lab, group of doctors

Transforming Healthcare

Lentiviral Vectors play an extremely important role in CAR-T therapy

There are 15 approved cell and gene therapies, eight of which use lentiviral vectors. With our network and partners within immunotherapy and biotech, we aim to transform the future of healthcare and provide easy access and affordable treatments to patients. Join us on our journey.

How it works
Immunotherapy activates the body's immune system to target and eliminate cancer cells, offering new hope for patients. CAR-T therapy genetically modifies patient's T cells to better recognize and destroy cancer cells. This groundbreaking approach has the potential to transform cancer treatment.

TEDx Tauranga | CAR T-cell therapy: Programming the immune system to treat cancer | Dr. Rob Weinkove, Clinical Director, Malaghan Institute of Medical Research

Lentiviral Vectors in CAR-T

Lentiviral vectors are crucial in CAR-T therapy, facilitating T-cell transformation. They enable efficient gene transfer, stable expression in non-dividing cells, and accommodate complex CAR genes while minimizing immune reactions.
FDA approved therapies with LVV

Eight FDA-approved LVV-based CGT include Kymriah, Yescarta, Tecartus, Breyanzi, Abecma, Carvykti, Zynteglo, and  Skysona. Several CAR-T therapies in clinical trials aim to target different antigens and improve specificity and side effects.
Key Role in CAR-T

  • Efficient Gene Transfer
  • Integration into the bodies own genome
  • Ability to Transduce Non-Dividing Cells
  • Large Packaging Capacity
  • Reduced Immunogenicity
Trans-Pacific Partnership Benefits

  • Reduced tariffs among member countries
  • Enhanced intellectual property rights
  • Regulatory coherence streamline regulations among member countries
  • Easier access to markets of all member countries
  • Supply chain efficiency
  • Provisions that protect foreign investment
  • Higher labor and environmental standards

Join Us

We are looking for Investors that consider adding a promising Biotech CDMO startup with purpose and a high growth potential to their portfolio.

We are located in New Zealand, a country with a highly skilled workforce, supportive government, favorable regulatory environment and strong economy.


.Get Wholesale Investor Pack -->|

100% Market Reach
By focusing on reaching and converting our targeted customers online 

Action Required

Now Open: Your Chance to Contribute!

Get | Wholesale Investor Pack

How To Invest

  • Sign up for Wholesale Investor Pack
  • Meet the founder
  • Sign CDA, and access Data Room
  • Complete due diligence
  • Close the deal

Estimated time to close: 3 months

Back To Top --->|